A 66-year-old male patient received abrocitinib 100 mg once daily orally for atopic dermatitis. After 3 and a half months, the patient′s condition was significantly improved and the dose of abrocitinib was reduced to 100 mg once every 2 days orally. After 35 days of continuous medication, the patient developed a sense of stuffiness in both ears, occasional tinnitus, and hearing loss. According to specialized examinations in otolaryngology, the sudden deafness was diagnosed, which was considered to be related to abrocitinib. Abrocitinib was stopped. After 38 days of treatments with nurturing nerves, improving circulation, his hearing basically returned to normal. After that, dermatitis recurred in the patient, and he received abrocitinib 100 mg once daily orally again. One month later, the patient developed hearing loss again. After 9 days of drug withdrawal, the patient′s tinnitus and other symptoms were basically relieved. Subsequently, abrocitinib was placed by dupilumab to treat atopic dermatitis in the patient. At a six-month of follow-up, symptoms such as tinnitus and hearing loss did not recur.

A 66-year-old male patient received abrocitinib 100 mg once daily orally for atopic dermatitis. After 3 and a half months, the patient′s condition was significantly improved and the dose of abrocitinib was reduced to 100 mg once every 2 days orally. After 35 days of continuous medication, the patient developed a sense of stuffiness in both ears, occasional tinnitus, and hearing loss. According to specialized examinations in otolaryngology, the sudden deafness was diagnosed, which was considered to be related to abrocitinib. Abrocitinib was stopped. After 38 days of treatments with nurturing nerves, improving circulation, his hearing basically returned to normal. After that, dermatitis recurred in the patient, and he received abrocitinib 100 mg once daily orally again. One month later, the patient developed hearing loss again. After 9 days of drug withdrawal, the patient′s tinnitus and other symptoms were basically relieved. Subsequently, abrocitinib was placed by dupilumab to treat atopic dermatitis in the patient. At a six-month of follow-up, symptoms such as tinnitus and hearing loss did not recur.